Newswise — February 18, 2022 – In men undergoing active surveillance as an alternative to immediate treatment for prostate cancer, a supervised exercise program can reduce anxiety and fear of cancer progression, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"In our study, a high-intensity interval training program yielded significant mental and physical health benefits for men who chose active surveillance for initial management of low-grade prostate cancer," comments senior author Kerry S. Courneya, PhD, of the University of Alberta, Edmonton, Canada. "These findings may be especially important for the subgroup of patients who switch to surgery or other treatment as a result of anxiety or fear that their prostate cancer will progress during active surveillance." The study was led by Dong-Woo Kang, PhD, who is now a postdoctoral fellow at the Dana-Farber Cancer Institute, Boston.
Psychological benefits of exercise training during AS for prostate cancer
Active surveillance (AS) is used as a way to monitor slow-growing, "low-risk" or localized prostate cancer rather than treating it right away. Men opting for AS typically undergo regular prostate-specific antigen (PSA) screenings, prostate exams, imaging tests and repeat biopsies in order to carefully monitor prostate cancer growth or progression without compromising long-term outcomes. The aim of AS is to avoid or delay unnecessary treatment and its side effects.
Understandably, many men experience increased anxiety and fear of cancer progression while they are on AS, which may reduce their quality of life (QOL). These concerns drive some patients to switch to definitive treatment, such as surgery or radiation therapy – even though their cancer has not progressed. "Interventions to reduce anxiety and fear of cancer progression in these men may improve QOL and reduce the chances of them opting for medically unnecessary treatments," Dr. Courneya and coauthors write.
In a study called the ERASE trial (Exercise During Active Surveillance for Prostate Cancer), the researchers evaluated a supervised, 12-week, high-intensity interval exercise training (HIIT) program for men undergoing AS. Published last year, the main study results showed significant improvement in cardiovascular fitness and reduced PSA levels in men assigned to the exercise program.
Could exercise also reduce anxiety and fear during AS? Dr. Courneya and colleagues performed a secondary analysis of these and other mental health outcomes among ERASE Trial participants. The analysis included 25 men assigned to the exercise program and a control group of 25 patients receiving usual care.
The HIIT program led to improvements in key patient-reported outcomes. Findings included a small but significant reduction in prostate cancer-related anxiety: a difference of about 3 points on a 54-point scale. Fear of cancer progression showed a larger decrease: by 2 points on a 12-point scale.
Exercise participants had improvement in hormonal symptoms such as lack of energy, feeling depressed or change in body weight. The HIIT program was also linked to reductions in stress and fatigue and a significant increase in self-esteem. Assessments of QOL suggested "borderline significant" increases in overall health status and emotional functioning.
Active surveillance has become an increasingly popular option for men with early-stage prostate cancer. However, recent studies have shown that many patients switch from AS to definitive treatment within a few years – sometimes with no evidence of cancer progression. "Our findings might be especially relevant for a subgroup of AS patients who opt for radical treatment to manage their distress," the researchers write.
Dr. Courneya comments: "Previous reports have suggested that exercise might help to manage anxiety in other cancer patient groups but our study is the first to show improvement in anxiety and fear of cancer progression experienced by men who opt for AS." The researchers call for larger studies to confirm their findings and to demonstrate the longer-term physical and mental health benefits of exercise for this growing group of patients.
DOR: 10.1097/JU.0000000000002334
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
RSS